XHKG6667
Market cap297mUSD
Jan 06, Last price
10.00HKD
1D
-8.93%
1Q
8.81%
IPO
-44.51%
Name
Mega Genomics Ltd
Chart & Performance
P/E
72.53
P/S
14.40
EPS
0.13
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
151m
+3.82%
Net income
30m
P
CFO
164m
P
Profile
Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services comprising ApoE gene testing package that assesses the lipid metabolism capacity and the risk for various related diseases, including Alzheimer's disease; folate metabolic capacity assessment, which analyzes genes related to folate metabolism capacity to determine the risk of developing hyperhomocysteinemia, cardiovascular, and cerebrovascular diseases; Parkinson's disease risk assessment; full-scale cancer risk assessment package; and cardiovascular and cerebrovascular disease risk assessment package. The company also provides advanced testing services, which include Hereditary breast cancer/ovarian cancer genetic testing, Septin9 colorectal cancer screening test, and RNF180/Septin9 gastric cancer screening test; and executive testing services, such as personal whole genome test and whole-exome sequencing package for adults. It offers testing services through self-developed laboratory-developed tests and In-vitro diagnostics testing kits. The company serves health checkup centers, hospitals, and various other customers. Mega Genomics Limited was founded in 2016 and is based in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 151,300 3.82% | 145,727 -38.56% | |||
Cost of revenue | 138,213 | 161,233 | |||
Unusual Expense (Income) | |||||
NOPBT | 13,087 | (15,506) | |||
NOPBT Margin | 8.65% | ||||
Operating Taxes | 6,141 | (3,800) | |||
Tax Rate | 46.92% | ||||
NOPAT | 6,946 | (11,706) | |||
Net income | 30,038 -270.50% | (17,618) -122.30% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (10,496) | 184,155 | |||
BB yield | 0.47% | -6.87% | |||
| Debt | |||||
Debt current | 12,528 | 6,480 | |||
Long-term debt | 61,961 | 15,492 | |||
Deferred revenue | 1,350 | 1,950 | |||
Other long-term liabilities | 1,950 | ||||
Net debt | (481,381) | (407,889) | |||
| Cash flow | |||||
Cash from operating activities | 163,684 | (6,911) | |||
CAPEX | (35,857) | (5,188) | |||
Cash from investing activities | (33,754) | (2,562) | |||
Cash from financing activities | (12,911) | 158,459 | |||
FCF | 65,817 | 229,726 | |||
| Balance | |||||
Cash | 526,270 | 399,831 | |||
Long term investments | 29,600 | 30,030 | |||
Excess cash | 548,305 | 422,575 | |||
Stockholders' equity | 254,454 | 217,129 | |||
Invested Capital | 440,285 | 415,171 | |||
ROIC | 1.62% | ||||
ROCE | 1.88% | ||||
| EV | |||||
Common stock shares outstanding | 211,767 | 206,292 | |||
Price | 10.46 -19.54% | 13.00 | |||
Market cap | 2,215,080 -17.40% | 2,681,799 | |||
EV | 1,733,699 | 2,273,910 | |||
EBITDA | 28,207 | (228) | |||
EV/EBITDA | 61.46 | ||||
Interest | 1,122 | 719 | |||
Interest/NOPBT | 8.57% | ||||